treatment outcome

Summary

Summary: Evaluation undertaken to assess the results or consequences of management and procedures used in combating disease in order to determine the efficacy, effectiveness, safety, and practicability of these interventions in individual cases or series.

Top Publications

  1. Jolly S, Cairns J, Yusuf S, Meeks B, Shestakovska O, Thabane L, et al. Design and rationale of the TOTAL trial: a randomized trial of routine aspiration ThrOmbecTomy with percutaneous coronary intervention (PCI) versus PCI ALone in patients with ST-elevation myocardial infarction undergoing primary PCI. Am Heart J. 2014;167:315-321.e1 pubmed publisher
    ..The trial uses an event-driven design and will recruit 10,700 patients. The TOTAL trial will determine the effect of routine manual aspiration thrombectomy during PPCI on clinically important outcomes. ..
  2. Carvajal R, Sosman J, Quevedo J, Milhem M, Joshua A, Kudchadkar R, et al. Effect of selumetinib vs chemotherapy on progression-free survival in uveal melanoma: a randomized clinical trial. JAMA. 2014;311:2397-405 pubmed publisher
    ..Uveal melanoma is characterized by mutations in GNAQ and GNA11, resulting in mitogen-activated protein kinase pathway activation...
  3. Holman R, Sourij H, Califf R. Cardiovascular outcome trials of glucose-lowering drugs or strategies in type 2 diabetes. Lancet. 2014;383:2008-17 pubmed publisher
  4. Robinson J, Nedergaard B, Rogers W, Fialkow J, Neutel J, Ramstad D, et al. Effect of evolocumab or ezetimibe added to moderate- or high-intensity statin therapy on LDL-C lowering in patients with hypercholesterolemia: the LAPLACE-2 randomized clinical trial. JAMA. 2014;311:1870-82 pubmed publisher
    ..Further studies are needed to evaluate the longer-term clinical outcomes and safety of this approach for LDL-C lowering. clinicaltrials.gov Identifier: NCT01763866. ..
  5. Nuttall T, Reece D, Roberts E. Life-long diseases need life-long treatment: long-term safety of ciclosporin in canine atopic dermatitis. Vet Rec. 2014;174 Suppl 2:3-12 pubmed publisher
    ..In conclusion, ciclosporin has a positive risk-benefit profile for the long-term management of canine AD. ..
  6. Sofen H, Smith S, Matheson R, Leonardi C, Calderon C, Brodmerkel C, et al. Guselkumab (an IL-23-specific mAb) demonstrates clinical and molecular response in patients with moderate-to-severe psoriasis. J Allergy Clin Immunol. 2014;133:1032-40 pubmed publisher
    ..IL-23 inhibition with a single dose of guselkumab results in clinical responses in patients with moderate-to-severe psoriasis, suggesting that neutralization of IL-23 alone is a promising therapy for psoriasis. ..
  7. Gianni L, Eiermann W, Semiglazov V, Lluch A, Tjulandin S, Zambetti M, et al. Neoadjuvant and adjuvant trastuzumab in patients with HER2-positive locally advanced breast cancer (NOAH): follow-up of a randomised controlled superiority trial with a parallel HER2-negative cohort. Lancet Oncol. 2014;15:640-7 pubmed publisher
  8. Caironi P, Tognoni G, Masson S, Fumagalli R, Pesenti A, Romero M, et al. Albumin replacement in patients with severe sepsis or septic shock. N Engl J Med. 2014;370:1412-21 pubmed publisher
    ..Funded by the Italian Medicines Agency; ALBIOS ClinicalTrials.gov number, NCT00707122.). ..
  9. Yamamoto M, Serizawa T, Shuto T, Akabane A, Higuchi Y, Kawagishi J, et al. Stereotactic radiosurgery for patients with multiple brain metastases (JLGK0901): a multi-institutional prospective observational study. Lancet Oncol. 2014;15:387-95 pubmed publisher

More Information

Publications32

  1. Jokubaitis V, Li V, Kalincik T, Izquierdo G, Hodgkinson S, Alroughani R, et al. Fingolimod after natalizumab and the risk of short-term relapse. Neurology. 2014;82:1204-11 pubmed publisher
    ..This study provides Class IV evidence that RRs are not higher in patients with multiple sclerosis switching to fingolimod from natalizumab compared to those patients switching to fingolimod from other therapies. ..
  2. Lannfelt L, Relkin N, Siemers E. Amyloid-ß-directed immunotherapy for Alzheimer's disease. J Intern Med. 2014;275:284-95 pubmed publisher
    ..In this review, we examine the presently ongoing Aß-directed immunotherapies that have passed clinical development Phase IIa. ..
  3. Kavanaugh A, Mease P, Gomez Reino J, Adebajo A, Wollenhaupt J, Gladman D, et al. Treatment of psoriatic arthritis in a phase 3 randomised, placebo-controlled trial with apremilast, an oral phosphodiesterase 4 inhibitor. Ann Rheum Dis. 2014;73:1020-6 pubmed publisher
    ..Apremilast was effective in the treatment of psoriatic arthritis, improving signs and symptoms and physical function. Apremilast demonstrated an acceptable safety profile and was generally well tolerated. NCT01172938. ..
  4. Ivarsen A, Asp S, Hjortdal J. Safety and complications of more than 1500 small-incision lenticule extraction procedures. Ophthalmology. 2014;121:822-8 pubmed publisher
    ..To evaluate the safety and complications of small-incision lenticule extraction (SMILE)...
  5. Sooriakumaran P, Nyberg T, Akre O, Haendler L, Heus I, Olsson M, et al. Comparative effectiveness of radical prostatectomy and radiotherapy in prostate cancer: observational study of mortality outcomes. BMJ. 2014;348:g1502 pubmed publisher
    ..To compare the survival outcomes of patients treated with surgery or radiotherapy for prostate cancer...
  6. Cortazar P, Zhang L, Untch M, Mehta K, Costantino J, Wolmark N, et al. Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis. Lancet. 2014;384:164-72 pubmed publisher
    ..The prognostic value is greatest in aggressive tumour subtypes. Our pooled analysis could not validate pathological complete response as a surrogate endpoint for improved EFS and OS. US Food and Drug Administration. ..
  7. Binjawadagi B, Dwivedi V, Manickam C, Ouyang K, Wu Y, LEE L, et al. Adjuvanted poly(lactic-co-glycolic) acid nanoparticle-entrapped inactivated porcine reproductive and respiratory syndrome virus vaccine elicits cross-protective immune response in pigs. Int J Nanomedicine. 2014;9:679-94 pubmed publisher
    ..A similar approach to control other respiratory diseases in food animals and humans appears to be feasible...
  8. Dougados M, Kissel K, Conaghan P, Mola E, Schett G, Gerli R, et al. Clinical, radiographic and immunogenic effects after 1 year of tocilizumab-based treatment strategies in rheumatoid arthritis: the ACT-RAY study. Ann Rheum Dis. 2014;73:803-9 pubmed publisher
    ..Despite a trend favouring the add-on strategy, these data suggest that both tocilizumab add-on and switch strategies led to meaningful clinical and radiographic responses. ..
  9. Rajan A, Carter C, Berman A, Cao L, Kelly R, Thomas A, et al. Cixutumumab for patients with recurrent or refractory advanced thymic epithelial tumours: a multicentre, open-label, phase 2 trial. Lancet Oncol. 2014;15:191-200 pubmed publisher
    ..Development of autoimmunity during treatment needs further investigation. Division of Cancer Treatment and Diagnosis at the National Cancer Institute (National Institutes of Health), ImClone Systems. ..
  10. Wasserstein D, Henry P, Paterson J, Kreder H, Jenkinson R. Risk of total knee arthroplasty after operatively treated tibial plateau fracture: a matched-population-based cohort study. J Bone Joint Surg Am. 2014;96:144-50 pubmed publisher
    ..3 times increase in likelihood compared with a matched group from the general population. Older patients and those with more severe fractures are also more likely to need total knee arthroplasty after repair of a tibial plateau fracture. ..
  11. Cockcroft D, Sears M. Are inhaled longacting ?2 agonists detrimental to asthma?. Lancet Respir Med. 2013;1:339-46 pubmed publisher
    ..When used for appropriate indications, LABAs should be combined with ICS in one inhaler so that monotherapy is not possible. ..
  12. Turgeon G, Souhami L, Cury F, Faria S, Duclos M, Sturgeon J, et al. Hypofractionated intensity modulated radiation therapy in combined modality treatment for bladder preservation in elderly patients with invasive bladder cancer. Int J Radiat Oncol Biol Phys. 2014;88:326-31 pubmed publisher
  13. Nam J, Ramiro S, Gaujoux Viala C, Takase K, Leon Garcia M, Emery P, et al. Efficacy of biological disease-modifying antirheumatic drugs: a systematic literature review informing the 2013 update of the EULAR recommendations for the management of rheumatoid arthritis. Ann Rheum Dis. 2014;73:516-28 pubmed publisher
    ..It addresses different treatment strategies with the potential for reduction in therapy, particularly with early disease control, and highlights emerging therapies. ..
  14. Williams M, Kodali S, Hahn R, Humphries K, Nkomo V, Cohen D, et al. Sex-related differences in outcomes after transcatheter or surgical aortic valve replacement in patients with severe aortic stenosis: Insights from the PARTNER Trial (Placement of Aortic Transcatheter Valve). J Am Coll Cardiol. 2014;63:1522-8 pubmed publisher
    ..This study sought to examine sex-specific differences in outcomes after surgical aortic valve replacement (SAVR) or transcatheter aortic valve replacement (TAVR) in high-risk patients with severe aortic stenosis...
  15. Thepot S, Itzykson R, Seegers V, Recher C, Raffoux E, Quesnel B, et al. Azacitidine in untreated acute myeloid leukemia: a report on 149 patients. Am J Hematol. 2014;89:410-6 pubmed publisher
    ..Outcomes observed in this high-risk AML population treated with AZA deserve comparison with those of patients treated intensively in prospective studies...
  16. Poddubnyy D, Hermann K, Callhoff J, Listing J, Sieper J. Ustekinumab for the treatment of patients with active ankylosing spondylitis: results of a 28-week, prospective, open-label, proof-of-concept study (TOPAS). Ann Rheum Dis. 2014;73:817-23 pubmed publisher
    ..Overall, ustekinumab was well tolerated. In this prospective, open-label, proof-of-concept clinical trial, ustekinumab treatment was associated with a reduction of signs and symptoms in active AS and was well tolerated. ..
  17. Guedj J, Yu J, Levi M, Li B, Kern S, Naoumov N, et al. Modeling viral kinetics and treatment outcome during alisporivir interferon-free treatment in hepatitis C virus genotype 2 and 3 patients. Hepatology. 2014;59:1706-14 pubmed publisher
    ..The model predicted that response-guided treatment could allow a reduction in mean treatment duration to 25.3 weeks and attain a 78.6% SVR rate...
  18. Martinot Peignoux M, Lapalus M, Asselah T, Marcellin P. HBsAg quantification: useful for monitoring natural history and treatment outcome. Liver Int. 2014;34 Suppl 1:97-107 pubmed publisher
    ..A level <100 IU/ml during six consecutive months could be a marker of a sustained response after treatment cessation. ..
  19. Jacobson I, Dore G, Foster G, Fried M, Radu M, Rafalsky V, et al. Simeprevir with pegylated interferon alfa 2a plus ribavirin in treatment-naive patients with chronic hepatitis C virus genotype 1 infection (QUEST-1): a phase 3, randomised, double-blind, placebo-controlled trial. Lancet. 2014;384:403-13 pubmed publisher
    ..The efficacy and safety of the combination of simeprevir, a one pill, once-daily, oral HCV NS3/4A protease inhibitor, plus peginterferon alfa 2a plus ribavirin were assessed in treatment-naive patients with HCV genotype 1 infection...
  20. Ussher J, Drucker D. Cardiovascular actions of incretin-based therapies. Circ Res. 2014;114:1788-803 pubmed publisher
    ..Improved understanding of the complex science of incretin-based therapies is required to optimize the selection of these therapeutic agents for the treatment of diabetic patients with cardiovascular disease...
  21. Giordano S, Temin S, Kirshner J, Chandarlapaty S, Crews J, Davidson N, et al. Systemic therapy for patients with advanced human epidermal growth factor receptor 2-positive breast cancer: American Society of Clinical Oncology clinical practice guideline. J Clin Oncol. 2014;32:2078-99 pubmed publisher
    ..To provide evidence-based recommendations to practicing oncologists and others on systemic therapy for patients with human epidermal growth factor receptor 2 (HER2) -positive advanced breast cancer...
  22. Branemark R, Berlin O, Hagberg K, Bergh P, Gunterberg B, Rydevik B. A novel osseointegrated percutaneous prosthetic system for the treatment of patients with transfemoral amputation: A prospective study of 51 patients. Bone Joint J. 2014;96-B:106-13 pubmed publisher
  23. Lange C, Abubakar I, Alffenaar J, Bothamley G, Caminero J, Carvalho A, et al. Management of patients with multidrug-resistant/extensively drug-resistant tuberculosis in Europe: a TBNET consensus statement. Eur Respir J. 2014;44:23-63 pubmed publisher